Showing 5491-5500 of 6633 results for "".
- Burt's Bees Natural Retinol Alternative Works Well in Sensitive Skinhttps://practicaldermatology.com/news/burts-bees-natural-retinol-alternative-works-well-in-sensitive-skin/2460430/Three new studies from Burt’s Bees highlight the safety and efficacy of Bakuchiol, a natural retinol alternative, as well as a new facial oil and lip balm. The findings were presented online at the American Academy of Dermatology (AAD
- Juvéderm Voluma XC Approved for Enhancement of the Chin Regionhttps://practicaldermatology.com/news/juvederm-voluma-xc-approved-for-enhancement-of-the-chin-region/2460426/The FDA has approved a new indication for Juvéderm Voluma XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21. The Juvéderm Collection of Fillers has the broadest portfolio of specifically tailored treatment options, and this latest ap
- Sciton Unveils mJOULE Platform Featuring BBL HERO And MOXIhttps://practicaldermatology.com/news/sciton-unveils-mjoule-platform-featuring-bbl-hero-and-moxi/2460420/Sciton Inc. is rolling out their mJOULE dual-wavelength platform which includes a new fractional treatment, MOXI, and BBL HERO. MOXI delivers non-ablative laser energy to revitalize skin and BroadBand Light HERO (High Energy Rapid Output) allows practitioners to treat the entire body wi
- ProTransit to Target Photodamage in Trials of New Nanoparticle Technologyhttps://practicaldermatology.com/news/protransit-to-target-photodamage-in-trials-of-new-nanoparticle-technology/2460418/ProTransit Nanotherapy plans to launch human clinical trials this summer with products that could target precursors of skin cancers. The company has developed therapies based nanoparticle technology invented at the University of Nebraska Medical Center to help prevent and potentially improve suns
- Dermata Reports Positive Results for Once-Weekly Topical Application of DMT310 in Acnehttps://practicaldermatology.com/news/dermata-reports-positive-results-for-once-weekly-topical-application-of-dmt310-in-acne/2460417/Dermata Therapeutics' lead clinical candidate, DMT310, performed well in a Phase 2b study of moderate-to-severe acne vulgaris. Once-weekly DMT310 achieved Investigator Global Assessment (IGA) success (2-point change & 0 or 1) in 44.4 percent of patients versus 17.8 percent
- New from Obagi: Two Sunscreens and a Hydrating Serumhttps://practicaldermatology.com/news/new-from-obagi-two-sunscreens-and-a-hydrating-serum/2460415/Obagi is launching two new Physical Defense Sunscreens and Daily Hydro-Drops. The new SUZANOBAGIMD Physical Defense Sunscreens, available in broad-spectrum SPF 40 and tinted SPF 50, defend against five light sources, including high energy visible light, or blue light, visible light
- Pfizer’s JAK Inhibitor Improves Moderate-to-Severe AD Symptomshttps://practicaldermatology.com/news/pfizers-jak-inhibitor-improves-mild-to-moderate-ad-symptoms/2460413/Results from the second pivotal trial for abrocitinib reinforce the potential symptom relief that this Janus kinase 1 (JAK1) inhibitor offers patients living with moderate to severe atopic dermatitis (AD). Abrocitinib is an investigational oral once-daily JAK1 inhibitor being studied in
- Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4’s Role in HS and ADhttps://practicaldermatology.com/news/kymera-therapeutics-initiates-enrollment-in-non-interventional-trial-evaluating-irak4s-role-in-hs-and-ad/2460411/Kymera Therapeutics Inc. has started enrollment in a non-interventional trial evaluating IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). Kymera is developing a selective orally administered IRAK4 degraders for the treatment of toll-like
- Zilxi Approved: First Topical Minocycline Treatment for Rosaceahttps://practicaldermatology.com/news/zilxi-approved-first-topical-minocycline-treatment-for-rosacea/2460408/The FDA has approved Zilxi™ (minocycline) topical foam, 1.5%, from Menlo Therapeutics for the treatment of inflammatory lesions of rosacea in adults. Zilxi, developed as FMX103 by Menlo’s wholly-owned subsidiary Foamix Pharmaceuticals Ltd., is the first minocycline product of any kind
- ASLMS Names New Boardhttps://practicaldermatology.com/news/aslms-names-new-board/2460406/The American Society for Laser Medicine and Surgery (ASLMS) announced its new board during the Board of Directors meeting on April 30, 2020. Thomas E. Rohrer, MD is the new President of ASLMS is the world's largest professional organization dedicated to promoting research, education, and high